Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 1:28 pm Sale | 2026-03-31 | 13G | RAPPORT THERAPEUTICS INC RAPP | Cormorant Asset Management, LP | 2,957,521 6.190% | -70,000 (-2.31%) | Filing History |
| 2026-02-17 3:02 pm Sale | 2025-12-31 | 13G | RAPPORT THERAPEUTICS INC RAPP | Cormorant Asset Management, LP | 3,027,521 6.350% | -165,000 (-5.17%) | Filing History |
| 2026-01-21 12:30 pm Purchase | 2025-12-31 | 13G | RAPPORT THERAPEUTICS INC RAPP | BlackRock, Inc. BLK | 2,397,549 5.030% | 2,397,549 (New Position) | Filing History |
| 2025-11-14 1:09 pm Purchase | 2025-09-30 | 13G | RAPPORT THERAPEUTICS INC RAPP | Cormorant Asset Management, LP | 3,192,521 6.700% | 251,600 (+8.56%) | Filing History |
| 2025-10-22 5:09 pm Sale | 2025-09-30 | 13G | RAPPORT THERAPEUTICS INC RAPP | JOHNSON & JOHNSON JNJ | 1,784,517 4.900% | -713,534 (-28.56%) | Filing History |
| 2025-09-18 5:32 pm Sale | 2025-09-11 | 13D | RAPPORT THERAPEUTICS INC RAPP | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 1,947,579 4.200% | -3,983 (-0.20%) | Filing History |
| 2025-02-13 4:15 pm Purchase | 2024-12-31 | 13G | RAPPORT THERAPEUTICS INC RAPP | Third Rock Ventures V L.P. | 7,135,233 19.500% | 7,135,233 (New Position) | Filing History |
| 2024-11-14 5:13 pm Purchase | 2024-09-30 | 13G | RAPPORT THERAPEUTICS INC RAPP | ARCH Venture Fund XII, L.P. | 3,728,738 10.200% | 3,728,738 (New Position) | Filing History |
| 2024-11-14 3:11 pm Purchase | 2024-09-30 | 13G | RAPPORT THERAPEUTICS INC RAPP | Cormorant Asset Management, LP | 2,940,921 8.040% | 638 (+0.02%) | Filing History |
| 2024-11-13 12:26 pm Purchase | 2024-11-14 | 13G | RAPPORT THERAPEUTICS INC RAPP | Capital International Investors | 2,602,529 7.100% | 2,602,529 (New Position) | Filing History |
| 2024-11-12 10:34 am Purchase | 2024-11-08 | 13G | RAPPORT THERAPEUTICS INC RAPP | FMR LLC | 5,486,468 14.999% | 503,117 (+10.10%) | Filing History |
| 2024-10-18 5:23 pm Purchase | 2024-09-30 | 13G | RAPPORT THERAPEUTICS INC RAPP | JOHNSON & JOHNSON JNJ | 2,498,051 6.800% | 2,498,051 (New Position) | Filing History |
| 2024-07-10 10:10 am Purchase | 2024-07-09 | 13G | RAPPORT THERAPEUTICS INC RAPP | FMR LLC | 4,983,351 13.624% | 4,983,351 (New Position) | Filing History |
| 2024-06-24 9:00 pm Sale | 2024-06-13 | 13G | RAPPORT THERAPEUTICS INC RAPP | GOLDMAN SACHS GROUP INC GS | 1,285,188 3.500% | -1,380,494 (-51.79%) | Filing History |
| 2024-06-21 4:52 pm Purchase | 2024-06-11 | 13G | RAPPORT THERAPEUTICS INC RAPP | GOLDMAN SACHS GROUP INC GS | 2,665,682 7.500% | 2,665,682 (New Position) | Filing History |
| 2024-06-20 4:01 pm Purchase | 2024-06-10 | 13G | RAPPORT THERAPEUTICS INC RAPP | Cormorant Asset Management, LP | 2,940,283 8.040% | 2,940,283 (New Position) | Filing History |
| 2024-06-14 3:59 pm Purchase | 2024-06-10 | 13D | RAPPORT THERAPEUTICS INC RAPP | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 1,951,562 5.500% | 1,951,562 (New Position) | Filing History |